# Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

> **NCT05410041** · PHASE1 · UNKNOWN · sponsor: **Beijing Boren Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CAR-NK-CD19 Cells

## Key facts

- **NCT ID:** NCT05410041
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-25
- **Primary completion:** 2023-04
- **Final completion:** 2024-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410041, "Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05410041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*